128 related articles for article (PubMed ID: 19692326)
1. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
Clement JM; McDermott DF
Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
6. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
[TBL] [Abstract][Full Text] [Related]
7. Aldesleukin for metastatic renal cell carcinoma?
Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
[No Abstract] [Full Text] [Related]
8. Aldesleukin in advanced renal cell carcinoma.
Schmidinger M; Hejna M; Zielinski CC
Expert Rev Anticancer Ther; 2004 Dec; 4(6):957-80. PubMed ID: 15606326
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
[TBL] [Abstract][Full Text] [Related]
13. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
14. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
15. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Atkins MB; Regan M; McDermott D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
[TBL] [Abstract][Full Text] [Related]
16. Improving the therapeutic index of IL-2.
McDermott DF
Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
[No Abstract] [Full Text] [Related]
17. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.
Shablak A; Sikand K; Shanks JH; Thistlethwaite F; Spencer-Shaw A; Hawkins RE
J Immunother; 2011 Jan; 34(1):107-12. PubMed ID: 21150719
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine for metastatic renal cell carcinoma.
Sonpavde G; Choueiri TK
Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
[TBL] [Abstract][Full Text] [Related]
19. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
20. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?
Dillman RO; Barth NM; VanderMolen LA; Fong WH; Mahdavi KK; McClure SE
Cancer Biother Radiopharm; 2011 Jun; 26(3):273-7. PubMed ID: 21711094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
